HUE046399T2 - Deoxinukleozid terápia kiegyensúlyozatlan nukleotid pool által okozott betegségek, ideértve a mitokondriális DNS depléciós szindrómát, kezelésére - Google Patents
Deoxinukleozid terápia kiegyensúlyozatlan nukleotid pool által okozott betegségek, ideértve a mitokondriális DNS depléciós szindrómát, kezeléséreInfo
- Publication number
- HUE046399T2 HUE046399T2 HUE16812537A HUE16812537A HUE046399T2 HU E046399 T2 HUE046399 T2 HU E046399T2 HU E16812537 A HUE16812537 A HU E16812537A HU E16812537 A HUE16812537 A HU E16812537A HU E046399 T2 HUE046399 T2 HU E046399T2
- Authority
- HU
- Hungary
- Prior art keywords
- diseases caused
- mitochondrial dna
- dna depletion
- including mitochondrial
- nucleotide pools
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180914P | 2015-06-17 | 2015-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE046399T2 true HUE046399T2 (hu) | 2020-03-30 |
Family
ID=57546446
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16812537A HUE046399T2 (hu) | 2015-06-17 | 2016-06-17 | Deoxinukleozid terápia kiegyensúlyozatlan nukleotid pool által okozott betegségek, ideértve a mitokondriális DNS depléciós szindrómát, kezelésére |
| HUE19156021A HUE050678T2 (hu) | 2015-06-17 | 2016-06-17 | Deoxinukleozid terápia ingadozó nukleotid pool által okozott betegségekhez, ideértve a mitokondriális DNS depléciós szindrómát |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19156021A HUE050678T2 (hu) | 2015-06-17 | 2016-06-17 | Deoxinukleozid terápia ingadozó nukleotid pool által okozott betegségekhez, ideértve a mitokondriális DNS depléciós szindrómát |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10471087B2 (hu) |
| EP (3) | EP3310362B1 (hu) |
| JP (3) | JP6599484B2 (hu) |
| KR (2) | KR20220018623A (hu) |
| CN (2) | CN107847512A (hu) |
| AU (3) | AU2016280293B2 (hu) |
| BR (2) | BR112017027079B1 (hu) |
| CA (1) | CA2989653A1 (hu) |
| CY (2) | CY1122605T1 (hu) |
| DK (2) | DK3310362T3 (hu) |
| ES (2) | ES2748556T3 (hu) |
| HK (1) | HK1252133A1 (hu) |
| HR (2) | HRP20191794T1 (hu) |
| HU (2) | HUE046399T2 (hu) |
| IL (3) | IL275256B2 (hu) |
| LT (2) | LT3310362T (hu) |
| MX (2) | MX2020000269A (hu) |
| PL (2) | PL3505174T3 (hu) |
| PT (2) | PT3310362T (hu) |
| RS (2) | RS60572B1 (hu) |
| RU (2) | RU2020112901A (hu) |
| SI (2) | SI3310362T1 (hu) |
| WO (1) | WO2016205671A1 (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10292996B2 (en) * | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| WO2016205671A1 (en) * | 2015-06-17 | 2016-12-22 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
| KR20180091924A (ko) | 2015-12-22 | 2018-08-16 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| CN109689103A (zh) | 2016-08-24 | 2019-04-26 | 周格尼克斯国际有限公司 | 用于抑制5-ht2b激动剂的形成的制剂及其使用方法 |
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| CA3096264A1 (en) * | 2018-04-12 | 2019-10-17 | Modis Therapeutics Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| AU2020334060A1 (en) * | 2019-08-19 | 2022-03-24 | Zogenix, Inc. | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
| CA3146835A1 (en) * | 2019-09-05 | 2021-03-11 | Mitorainbow Therapeutics, Inc. | Treating mitochondrial dna depletion disorders |
| JP2023518395A (ja) | 2020-03-19 | 2023-05-01 | インテリア セラピューティクス，インコーポレイテッド | 指向性ゲノム編集のための方法及び組成物 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20220096514A1 (en) * | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
| WO2022145439A1 (ja) * | 2020-12-28 | 2022-07-07 | ヤマサ醤油株式会社 | 筋萎縮抑制剤及び筋萎縮を抑制させる方法 |
| JP2024515025A (ja) * | 2021-03-26 | 2024-04-04 | ゾジェニックス，インコーポレイテッド | プリン及びピリミジンを含有する水性溶液及びその使用 |
| CA3222484A1 (en) * | 2021-06-18 | 2022-12-22 | Daniel DIPIETRO | Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools |
| US20240016938A1 (en) * | 2022-07-12 | 2024-01-18 | Zogenix Mds, Inc. | Methods for increasing the bioavailability of nucleoside medicinal agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2300381C2 (ru) * | 1998-08-10 | 2007-06-10 | Айденикс (Кайман) Лимитед | β-L-2'-ДЕЗОКСИНУКЛЕОЗИДЫ ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА В |
| US7638501B1 (en) * | 1999-02-23 | 2009-12-29 | The Regents Of The University Of California | Method of treatment of mitochondrial disorders |
| ATE275406T1 (de) * | 2000-05-26 | 2004-09-15 | Idenix Cayman Ltd | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
| WO2012125848A2 (en) * | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| RU2745611C2 (ru) * | 2015-06-05 | 2021-03-29 | Фундасио Оспиталь Университари Валь Д'Эброн - Институт Де Ресерка | Лечение митохондриальных заболеваний |
| WO2016205671A1 (en) * | 2015-06-17 | 2016-12-22 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
-
2016
- 2016-06-17 WO PCT/US2016/038110 patent/WO2016205671A1/en active Application Filing
- 2016-06-17 CN CN201680045355.XA patent/CN107847512A/zh active Pending
- 2016-06-17 MX MX2020000269A patent/MX2020000269A/es unknown
- 2016-06-17 KR KR1020227002790A patent/KR20220018623A/ko not_active Application Discontinuation
- 2016-06-17 EP EP16812537.5A patent/EP3310362B1/en active Active
- 2016-06-17 KR KR1020187001496A patent/KR20180039624A/ko active Application Filing
- 2016-06-17 PT PT168125375T patent/PT3310362T/pt unknown
- 2016-06-17 CA CA2989653A patent/CA2989653A1/en active Pending
- 2016-06-17 PL PL19156021T patent/PL3505174T3/pl unknown
- 2016-06-17 MX MX2017016425A patent/MX2017016425A/es active IP Right Grant
- 2016-06-17 SI SI201630439T patent/SI3310362T1/sl unknown
- 2016-06-17 PT PT191560218T patent/PT3505174T/pt unknown
- 2016-06-17 LT LT16812537T patent/LT3310362T/lt unknown
- 2016-06-17 RU RU2020112901A patent/RU2020112901A/ru unknown
- 2016-06-17 CN CN202310757609.2A patent/CN116726035A/zh active Pending
- 2016-06-17 SI SI201630830T patent/SI3505174T1/sl unknown
- 2016-06-17 HU HUE16812537A patent/HUE046399T2/hu unknown
- 2016-06-17 BR BR112017027079-0A patent/BR112017027079B1/pt active IP Right Grant
- 2016-06-17 US US15/736,092 patent/US10471087B2/en active Active
- 2016-06-17 ES ES16812537T patent/ES2748556T3/es active Active
- 2016-06-17 ES ES19156021T patent/ES2808148T3/es active Active
- 2016-06-17 PL PL16812537T patent/PL3310362T3/pl unknown
- 2016-06-17 BR BR122020021913-0A patent/BR122020021913B1/pt active IP Right Grant
- 2016-06-17 AU AU2016280293A patent/AU2016280293B2/en active Active
- 2016-06-17 JP JP2017566000A patent/JP6599484B2/ja active Active
- 2016-06-17 RS RS20200779A patent/RS60572B1/sr unknown
- 2016-06-17 DK DK16812537.5T patent/DK3310362T3/da active
- 2016-06-17 LT LTEP19156021.8T patent/LT3505174T/lt unknown
- 2016-06-17 EP EP19178700.1A patent/EP3569236A1/en active Pending
- 2016-06-17 HU HUE19156021A patent/HUE050678T2/hu unknown
- 2016-06-17 DK DK19156021.8T patent/DK3505174T3/da active
- 2016-06-17 RU RU2018101305A patent/RU2721492C2/ru active
- 2016-06-17 RS RS20191295A patent/RS59724B1/sr unknown
- 2016-06-17 EP EP19156021.8A patent/EP3505174B1/en active Active
- 2016-06-17 IL IL275256A patent/IL275256B2/en unknown
-
2017
- 2017-12-14 IL IL256331A patent/IL256331B/en active IP Right Grant
-
2018
- 2018-09-07 HK HK18111524.2A patent/HK1252133A1/zh unknown
-
2019
- 2019-09-26 US US16/583,852 patent/US11110111B2/en active Active
- 2019-10-02 JP JP2019182191A patent/JP6675037B2/ja active Active
- 2019-10-02 JP JP2019182192A patent/JP7036782B2/ja active Active
- 2019-10-03 HR HRP20191794TT patent/HRP20191794T1/hr unknown
- 2019-10-30 CY CY20191101127T patent/CY1122605T1/el unknown
-
2020
- 2020-06-09 IL IL275255A patent/IL275255B/en active IP Right Grant
- 2020-06-15 HR HRP20200949TT patent/HRP20200949T1/hr unknown
- 2020-06-17 AU AU2020204042A patent/AU2020204042B2/en active Active
- 2020-06-25 CY CY20201100578T patent/CY1123107T1/el unknown
-
2021
- 2021-04-28 US US17/242,822 patent/US11666592B2/en active Active
- 2021-10-11 AU AU2021250841A patent/AU2021250841B2/en active Active
-
2023
- 2023-04-24 US US18/138,432 patent/US20230277577A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275255B (en) | Deoxynucleoside treatment for diseases caused by unbalanced stores of nucleotides including mitochondrial DNA depletion syndromes | |
| IL256634A (en) | Therapeutic oligonucleotides | |
| DK3294323T3 (da) | Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet | |
| DK3171929T3 (da) | Dosering til nervestimulation | |
| DK3262066T4 (da) | Genterapi | |
| EP3781671A4 (en) | GENE THERAPY FOR DISEASES CAUSED BY IMPACTED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | |
| GB201412973D0 (en) | Adjustable steering columns | |
| IL254632A0 (en) | RNA interference-mediated therapy for neurodegenerative diseases | |
| GB201507104D0 (en) | Nucleic acid construct | |
| GB2524625B (en) | Purification column | |
| IL259864A (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| GB201521217D0 (en) | Dosage regimens | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider | |
| PL3244860T3 (pl) | Kolumna stołu operacyjnego | |
| DK3261679T3 (da) | Genterapi til synsforbedring | |
| GB201512617D0 (en) | Single-stranded DNA sensor | |
| FI20155776A (fi) | Ballistisen suojarakenteen valmistusmenetelmä | |
| FI11038U1 (fi) | Aitapylväs | |
| GB201519323D0 (en) | Nucleic acid analysis | |
| GB201503845D0 (en) | Nucleic acid analysis |